Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

FORT MEYERS, Fla. — There were times last season, even after he came off the injured list, when Triston Casas still felt a twinge of pain in his ribs when he took a particularly hard swing.

For the fourth time in five months, the Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest ...

Moderna (MRNA) reported mixed fourth quarter earnings and full-year 2024 earnings Friday. Moderna's stock was down 5% in premarket trading on the earnings results but rose more than 2% sharply ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...

Modernism played an undeniable role in the renewal of architectural ideals, contributing a new attitude toward understanding ...

Despite negative financials, technical analysis indicates potential support at $28-30, justifying a "hold" position rather than a "sell.". Moderna (NASDAQ:MRNA), which went public at $22 in 2018 ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion ...

Following four straight sessions of gains, Moderna (NASDAQ:MRNA) shares continued to trade higher in the premarket on Friday after the company received a tender to supply its COVID-19 vaccine in ...

The American pharmaceutical company Moderna is developing an mRNA-based vaccine candidate for norovirus, designated as mRNA-1403. This vaccine is designed to protect against multiple norovirus ...

Sales at the once-high-flying biotech will likely continue to shrink for a while. But Moderna has a new cash cow in development, along with other potential winners. The U.S. government should ...